search again

Brexucabtagene Autoleucel (Tecartus)

Nationwide rates for HCPCS C9073

Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $645,654 · 10th–90th $389,045$1,380,3840%50%10th90th$645,654Professionalmedian $407,380 · 10th–90th $631$977,2370%20%10th90th$407,380$50.0$500.0$5.0K$50.0K$500.0K$5.0M

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Need provider-level prices? Contact us.

Insurance Carrier
BCBS
Setting
Facility
Modifier
Global
Typical Low
$676,082.98
Median
$1,905,460.72
Typical High
$5,370,317.96
United
Setting
Facility
Modifier
Global
Typical Low
$1,258.93
Median
$1,258.93
Typical High
$1,258.93
United
Setting
Professional
Modifier
Global
Typical Low
$446,683.59
Median
$446,683.59
Typical High
$562,341.33